Toggle Main Menu Toggle Search

Open Access padlockePrints

Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content

Lookup NU author(s): Dr Balasubramanian Ravikumar, Jean Gerrard, Dr Michael FirbankORCiD, Annette Lane, Professor Roy Taylor


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Objective: Hepatic triglyceride is closely associated with hepatic insulin resistance and is known to be decreased by thiazolididinediones. We studied the effect of pioglitazone on hepatic triglyceride content and the consequent effect on postprandial endogenous glucose production (EGP) in type 2 diabetes. Research Design and Methods: Ten subjects with type 2 diabetes on sulfonylurea therapy were treated with pioglitazone (30 mg daily) for 16 weeks. EGP was measured using a dynamic isotopic methodology after a standard liquid test meal both before and after pioglitazone treatment. Liver and muscle triglyceride levels were measured by H-1 magnetic resonance spectroscopy, and intra-abdominal fat content was measured by magnetic resonance imaging. Results: Pioglitazone treatment reduced mean plasma fasting glucose and mean peak postprandial glucose levels. Fasting EGP decreased after pioglitazone treatment (16.6 +/- 1.0 vs. 12.2 +/- 0.7 mu mol center dot kg(-1) center dot min(-1), P = 0.005). Between 80 and 260 min postprandially, EGP was twofold lower on pioglitazone (2.58 +/- 0.25 vs. 1.26 +/- 0.30 mu mol center dot kg(-1) center dot min(-1), P

Publication metadata

Author(s): Ravikumar B, Gerrard J, Man CD, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R

Publication type: Article

Publication status: Published

Journal: Diabetes

Year: 2008

Volume: 57

Issue: 9

Pages: 2288-2295

ISSN (print): 0012-1797

ISSN (electronic): 1939-327X

Publisher: American Diabetes Association


DOI: 10.2337/db07-1828


Altmetrics provided by Altmetric